229 related articles for article (PubMed ID: 19189371)
1. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.
Peeters M; Siena S; Van Cutsem E; Sobrero A; Hendlisz A; Cascinu S; Kalofonos H; Devercelli G; Wolf M; Amado RG
Cancer; 2009 Apr; 115(7):1544-54. PubMed ID: 19189371
[TBL] [Abstract][Full Text] [Related]
2. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
Amado RG; Wolf M; Peeters M; Van Cutsem E; Siena S; Freeman DJ; Juan T; Sikorski R; Suggs S; Radinsky R; Patterson SD; Chang DD
J Clin Oncol; 2008 Apr; 26(10):1626-34. PubMed ID: 18316791
[TBL] [Abstract][Full Text] [Related]
3. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
Van Cutsem E; Peeters M; Siena S; Humblet Y; Hendlisz A; Neyns B; Canon JL; Van Laethem JL; Maurel J; Richardson G; Wolf M; Amado RG
J Clin Oncol; 2007 May; 25(13):1658-64. PubMed ID: 17470858
[TBL] [Abstract][Full Text] [Related]
4. A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer.
Kim TW; Elme A; Kusic Z; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Bilic A; Manojlovic N; Dong J; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
Br J Cancer; 2016 Nov; 115(10):1206-1214. PubMed ID: 27736842
[TBL] [Abstract][Full Text] [Related]
5. Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.
Thaler J; Karthaus M; Mineur L; Greil R; Letocha H; Hofheinz R; Fernebro E; Gamelin E; Baños A; Köhne CH
BMC Cancer; 2012 Sep; 12():438. PubMed ID: 23020584
[TBL] [Abstract][Full Text] [Related]
6. Panitumumab: in metastatic colorectal cancer with wild-type KRAS.
Weber J; McCormack PL
BioDrugs; 2008; 22(6):403-11. PubMed ID: 18998757
[TBL] [Abstract][Full Text] [Related]
7. A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.
Wang J; Zhao Z; Barber B; Sherrill B; Peeters M; Wiezorek J
Br J Cancer; 2011 Jun; 104(12):1848-53. PubMed ID: 21610704
[TBL] [Abstract][Full Text] [Related]
8. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on panitumumab in metastatic colorectal cancer.
Keating GM
BioDrugs; 2010 Aug; 24(4):275-8. PubMed ID: 20623992
[TBL] [Abstract][Full Text] [Related]
10. [Panitumumab-treatment of metastatic colorectal cancer].
Pikó B
Magy Onkol; 2009 Jun; 53(2):135-42. PubMed ID: 19581179
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab.
Odom D; Barber B; Bennett L; Peeters M; Zhao Z; Kaye J; Wolf M; Wiezorek J
Int J Colorectal Dis; 2011 Feb; 26(2):173-81. PubMed ID: 21190026
[TBL] [Abstract][Full Text] [Related]
12. Panitumumab: a review of its use in metastatic colorectal cancer.
Keating GM
Drugs; 2010 May; 70(8):1059-78. PubMed ID: 20481659
[TBL] [Abstract][Full Text] [Related]
13. FDA drug approval summary: panitumumab (Vectibix).
Giusti RM; Shastri KA; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 May; 12(5):577-83. PubMed ID: 17522246
[TBL] [Abstract][Full Text] [Related]
14. Integration of panitumumab into the treatment of colorectal cancer.
Gravalos C; Cassinello J; García-Alfonso P; Jimeno A
Crit Rev Oncol Hematol; 2010 Apr; 74(1):16-26. PubMed ID: 19616446
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial.
Au HJ; Karapetis CS; O'Callaghan CJ; Tu D; Moore MJ; Zalcberg JR; Kennecke H; Shapiro JD; Koski S; Pavlakis N; Charpentier D; Wyld D; Jefford M; Knight GJ; Magoski NM; Brundage MD; Jonker DJ
J Clin Oncol; 2009 Apr; 27(11):1822-8. PubMed ID: 19273701
[TBL] [Abstract][Full Text] [Related]
16. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.
Peeters M; Oliner KS; Parker A; Siena S; Van Cutsem E; Huang J; Humblet Y; Van Laethem JL; André T; Wiezorek J; Reese D; Patterson SD
Clin Cancer Res; 2013 Apr; 19(7):1902-12. PubMed ID: 23325582
[TBL] [Abstract][Full Text] [Related]
17. An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer.
Poulin-Costello M; Azoulay L; Van Cutsem E; Peeters M; Siena S; Wolf M
Target Oncol; 2013 Jun; 8(2):127-36. PubMed ID: 23625191
[TBL] [Abstract][Full Text] [Related]
18. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer.
Hecht JR; Mitchell E; Neubauer MA; Burris HA; Swanson P; Lopez T; Buchanan G; Reiner M; Gansert J; Berlin J
Clin Cancer Res; 2010 Apr; 16(7):2205-13. PubMed ID: 20332321
[TBL] [Abstract][Full Text] [Related]
19. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.
Siena S; Peeters M; Van Cutsem E; Humblet Y; Conte P; Bajetta E; Comandini D; Bodoky G; Van Hazel G; Salek T; Wolf M; Devercelli G; Woolley M; Amado RG
Br J Cancer; 2007 Dec; 97(11):1469-74. PubMed ID: 18040272
[TBL] [Abstract][Full Text] [Related]
20. On-treatment markers as predictors to guide anti-EGFR MoAb treatment in metastatic colorectal cancer: a systematic review with meta-analysis.
Hu J; Zhang Z; Zheng R; Cheng L; Yang M; Li L; Liu B; Qian X
Cancer Chemother Pharmacol; 2017 Feb; 79(2):275-285. PubMed ID: 27878357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
